Innate Pharma and Sanofi announce that Sanofi has exercised its license option for an NK Cell Engager program in solid tumors, derived from Innate's ANKET platform, in accordance with the terms of the license agreement signed in December 2022.

After a period of research collaboration, Sanofi will be responsible for product development, manufacturing and commercialization. It retains a license option for an additional ANKET target in accordance with the agreement.

Innate will receive a payment of 15 million euros for exercising this option. It is eligible for milestone payments linked to the achievement of targets, as well as royalties on potential net sales of up to 1.35 billion euros.

Copyright (c) 2023 CercleFinance.com. All rights reserved.